3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Neuroendocrine Tumors
29
Meningioma
5
Gastro-enteropancreatic neuroendocrine tumor
5
Paraganglioma
4
Carcinoma, Neuroendocrine
4
Pheochromocytoma
3
Neuroblastoma
3
Neoplasms, Germ Cell and Embryonal
2
Neoplasms
2
Medulloblastoma
2
Glioma
2
Ependymoma
2
Carcinoma, Merkel Cell
2
Carcinoma, Medullary
2
Carcinoid Tumor
2
Adenoma, Islet Cell
2
Stomach Neoplasms
1
Somatostatinoma
1
Small Cell Lung Carcinoma
1
Serotonin Syndrome
1
Sarcoma, Synovial
1
Recurrence
1
Prostatic Neoplasms
1
Pituitary Neoplasms
1
Parathyroid Neoplasms
1
Pancreatic Neoplasms
1
Pancreatic Diseases
1
Osteosarcoma
1
Neuroectodermal Tumors
1
Neoplasms, Nerve Tissue
1
Interventions
telotristat ethyl
3
telotristat
1
lutetium Lu 177 dotatate
1
alpha-methyltryptophan
1
Panitumumab
1
Octreotide
1
Magnetic Resonance Spectroscopy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Serotonin Syndrome
×
lutetium Lu 177 dotatate
×
Clear all
NCT04039516
2020-08-04
CHARRT
King's College Hospital NHS Trust
Phase 2
Unknown
20 enrolled